A defensive earnings story stood out on the Egyptian stock exchange today even as the broader market weakened. On Monday, May 18, 2026, the EGX 30 index fell 0.68% to 52,007.0 points, while Ibnsina Pharma rose 1.5% to EGP 11.73 after releasing consolidated financial results, according to official EGX disclosures.
That divergence matters because it came against a tougher macro backdrop. The USD/EGP rose 0.79% to 53.27, extending the currency pressure that has dominated Egyptian equities since the devaluations of 2022-2024, while Brent crude climbed 1.4% on the day to $110.84 a barrel, taking its weekly gain to 4.9%. For listed Egyptian companies, especially those reliant on imported inputs, that combination means higher landed costs, tighter working-capital management, and more scrutiny on pricing power.
Market context: EGX 30 slips as breadth turns negative
The broader tone on the Cairo stock market was clearly risk-off. Market breadth came in at 12 gainers, 29 losers, and 2 unchanged out of 43 tracked names, a weak participation profile that suggests the decline was not confined to a handful of index heavyweights. In that setting, Ibnsina’s 1.5% gain looks more like an earnings-driven re-rating than a random move.
Turnover, however, remained robust. led value traded at , followed by at , at , at , and at . High turnover alongside a falling index usually points to rotation rather than a collapse in liquidity. Afrivestia highlighted a similar pattern in its earlier coverage, .